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 Introduction: Chimeric antigen receptor (CAR) T-cell therapy is a new treatment 
for hematologic malignancies including aggressive B-cell non-Hodgkin’s lymphoma 
(NHL). Although it has provided an effective treatment option for patients who have few 
options, CAR T-cell therapy does have many associated toxicities. Prolonged cytopenias 
are one of the lesser understood toxicities that can affect upwards of 40% of patients. 
Methods: In this retrospective study, we reviewed 106 patients who received commercial 
CAR T-cell therapy between November 2017 and September 2019. Prolonged cytopenias 
were defined as having absolute neutrophil count (ANC) <1000/mm3, platelets (PLT) 
<50,000/mm3, and/or hemoglobin (Hgb) <10 g/dL at least once after 30 days post-CAR 
T-cell infusion. Furthermore, if only one incidence of cytopenia was recorded 30 days 
post infusion, we required that the patient had to have received either a transfusion or 
granulocyte-colony stimulating factor (GCSF) after the date of the recorded cytopenic 
value to be considered a part of the cytopenic cohort. Results: 22 patients met the criteria 
of having prolonged cytopenias. 64% of the cytopenic cohort had >1 type of prolonged 
cytopenias. Anemia was the most prevalent affecting 72% of cytopenic patients. The 
length of time from diagnosis of aggressive B-cell NHL to date of CAR T-cell infusion 
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was found to be positively correlated with an increased risk of developing prolonged 
cytopenias following CAR T-cell therapy. Additional risk factors associated with an 
increased risk of delayed cytopenias by univariate analysis included neutropenia on the 
day of infusion (day 0), a high C-reactive protein (CRP) before lymphodepletion and on 
day 0, day 0 PLT count, and Hgb before lymphodepletion and on day 0.  On multivariate 
analysis, only high CRP before lymphodepletion was associated with an increased risk of 
prolonged cytopenias while high ferritin and PLT values on day 0 were associated with 
not developing prolonged cytopenias. There was no statistical difference between the 
cytopenic and non-cytopenic cohorts in rates of progression free survival (PFS) and 
overall survival (OS). Also, no difference was seen in rates or severity of other toxicities 
between cohorts.  41% of the cytopenic cohort experienced infectious complications post-
infusion with one patient dying from their infectious complications. However, there was 
no association with incidence of infection and prolonged cytopenias when compared to 
the incidence of infection in the non-cytopenic cohort. Conclusions: A longer time from 
diagnosis of aggressive B-cell NHL to time of CAR T-cell infusion was associated with 
prolonged cytopenias while number of lines of prior chemotherapy and rate of prior high 
dose chemotherapy with an autologous stem cell transplant (HD-ASCT) were not 
associated. It would be valuable to confirm this association and why it is associated since 
the other two factors were not. We lacked bone marrow biopsies before CAR T-cell 
infusion and did not have bone marrow biopsies for many patients after CAR T-cell 
infusion. It would be beneficial to collect data regarding bone marrow biopsies from 
these time points to highlight any changes that could be related to CAR T-cell therapy. 
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Cytogenetic information of individual patient’s diseases would be worth analyzing to 
help determine if there are biological factors associated with prolonged cytopenias in 
response to CAR T-cell therapy. Additional studies should investigate the laboratory 
values we found to have associations with either cohort to help identify possible 
predictive values providers could use to identify patients at higher risk of having 
prolonged cytopenias. There is also a need to see if specific prior chemotherapy regimens 
increase a patient’s risk of having prolonged cytopenias. Overall, since prolonged 
cytopenias after CAR T-cell infusions have not been heavily investigated, further 
investigation is needed to better understand the predictive factors and identify possible 
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Aggressive B-cell Non-Hodgkin’s Lymphoma  
Non-Hodgkin’s Lymphoma (NHL) accounts for approximately 4% of all cancer, 
and an expected 77,240 people will be diagnosed with NHL this year.1,2 Moreover, NHL 
is the eighth and ninth most common cause of cancer-related death in women and men, 
respectively.2 NHL is a broad classification of lymphomas that encompasses more than 
90 specific types of lymphoma.3 NHL are grouped into two categories: indolent and 
aggressive lymphomas.4 Indolent lymphomas are distinguished by having long survival 
time, often many years, and quick responses to treatments, but a lack of a curative 
standard therapies.4 Conversely, aggressive lymphomas typically exhibit rapid 
progression without therapy and can be cured with standard chemotherapies.4 However, 
survival is short when patients are not able to be cured by chemotherapy.4  
More specifically, B-cell lymphomas make up approximately 85% of all NHL in 
the United States.5 The category of aggressive B-cell lymphoma includes the diagnoses of 
diffuse large B-cell lymphoma (DLBCL), transformed follicular (TFL) or transformed 
marginal zone lymphoma, high-grade B-cell lymphoma (HGBL), primary mediastinal B-
cell lymphoma (PMBCL), T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL), 
and several others.6,7 DLBCL is the most common of these subtypes and constitutes about 
a third of all NHL.2    
DLBCL is classified as diffuse proliferation of large cells with high mitotic rates.2 
The tumor cells’ large size is the only feature tying DLBCL together; the different types 
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of DLBCL may otherwise have varying morphologies.2 DLBCL can either occur due to 
transformation from indolent lymphomas or can be de novo in origin. 8 Transformation 
can also be seen from other indolent lymphomas including marginal zone lymphoma.7 
Studies have found that patients with de novo DLBCL have a better prognosis than 
transformed patients.8 Conversely, HGBL is associated with worse outcomes than 
DLBCL even after receiving intensive chemotherapy regimens.9,10 Approximately 30% of 
patients diagnosed with HGBL previously had another form of B-cell NHL.10  
PMBCL is another form of aggressive B-cell NHL most commonly found in the 
mediastinum of young women.11 It often appears as groups of large malignant cells with 
abundant cytoplasm that is typically separated by eosinophilic fibrosis.11 Patients with 
PMBCL typically have better survival rates than patients with DLBCL.11 Another form of 
aggressive B-cell NHL, called gray zone lymphoma, gets its name from having genetics 
similar to both PMLBCL and classical Hodgkin’s Lymphoma (CHL).11 It is typically 
seen in young men and has a worse prognosis than that of PMLBCL and CHL.11 
Lastly, THRLBCL is another form of aggressive B-cell NHL that is most 
commonly seen in middle aged men.11 THRLBCL often has involvement in the liver, 
spleen, and bone marrow.12 Additionally, THRLBCL and another lymphoma, nodular 
lymphocyte predominant Hodgkin lymphoma, appear to be biologically connected with 
THRLBCL being the more aggressive of the two and having a poorer prognosis.11  
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Standard Treatment for Aggressive B-cell NHL Prior to CAR T-cell Therapy 
Regarding treatment for aggressive B-cell NHL, almost all patients are treated 
with an anti-CD20 monoclonal antibody and induction regimen containing 
anthracycline.13 The widely accepted first line therapy is R-CHOP, which stands for the 
following pharmaceutical agents: rituximab, cyclophosphamide, doxorubicin, vincristine, 
and prednisone.8,13 For patients with aggressive B-cell NHL, approximately 50-60% 
achieve and maintain a durable complete response (CR).6,8,14 Patients with relapse or 
refractory aggressive B-cell NHL after their first line of therapy not only have a low cure 
rate with typical therapy options but, without further treatment, also have a life 
expectancy in the range of months.8,13,14 
 The second treatment option for patients with relapsed or refractory aggressive 
B-cell NHL would be undergoing a salvage chemoimmunotherapy regimen with the goal 
of proceeding to high dose chemotherapy with an autologous stem cell transplant (HD-
ASCT).8 Some common second line treatment regimens are rituximab, isofamide, 
carboplatin, and etoposide (RICE); rituximab, dexamethasone, cytarabine, and cisplatin 
(R-DHAP); and rituximab, gemcitabine, dexamethasone, and cisplatin (R-GDP).13 All 
three have similar efficacy with about one-third of patients continuing to HD-ASCT.13  
In regards to the clinical importance of HD-ASCT, one retrospective study found 
that the overall survival (OS) and the progression free survival (PFS) in patients with 
primary relapsed DLBCL who received salvage chemotherapy without proceeding to 
HD-ASCT was 38% and 29%, respectively.15 Meanwhile, patients who received both 
salvage chemotherapy and HD-ASCT had an OS of 65% and a PFS of 60%.16 However, 
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another study conducted by Gisselbrecht and colleagues found that patients with relapsed 
large B-cell lymphoma who relapsed within the first year of being diagnosed had a 3-year 
event-free survival (EFS) of 20% while the patients who relapsed more than a year after 
being diagnosed had a 3 year EFS of 45%.15 The researchers also found that patients with 
relapsed large B-cell lymphoma who had received prior rituximab had a 3-year EFS of 
20% compared to the 3-year EFS of 45% seen in their counterparts that had not received 
a rituximab-containing regimen.15 These findings supported the need for developing more 
treatment options for patients with relapsed or refractory aggressive B-cell NHL.  
 
Chimeric Antigen Receptor T-cell History 
 Chimeric antigen receptor (CAR) T-cell therapy is a new treatment with relatively 
fast development since the discovery of T-cells in 1961. T-cell engineering began in 1992 
when immunologist Michel Sadelain began using retroviral vectors along with other 
genetic engineering tools to enhance the effectiveness of T-cells in the body.17 In 1993, 
the first generation of CARs were developed; they were not clinically effective since they 
were unable to survive in vivo.17 However, in 1998, a costimulatory molecule was added 
to engineered T-cells, which allowed them to stay active in the human body17 The first 
effective CAR T-cells were developed in 2002 for prostate cancer.17  
Shortly thereafter, in 2003, the second generation of CARs were built to target 
CD19 cells and were proven to kill leukemia cells in mice.17 The first human study using 
CARs was published in 2013 and in 2014, the Food and Drug Administration, FDA, gave 
CD-19 directed CAR T-cells Breakthrough Designation17 In 2017, CAR T-cell therapy 
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was approved first for children and young adults with relapsed or refractory acute 
lymphoblastic leukemia, ALL, and then for patients with relapsed or refractory DLBCL 
who had previous had two lines of systemic therapy.17,18 
 
CAR T-cell Structure and Function 
 In regard to their structure, CARs most commonly have an extracellular target-
binding domain, a hinge region, a transmembrane domain, and one or more intracellular 
domains.19 The extracellular target-binding domain, typically a single-chain variable 
fragment, dictates the capability of the CAR to bind to an antigen, and when bound, 
activates the T cells.19,20 This region allows for the T-cell to recognize its target antigens 
without using the major histocompatibility complex (MHC) or the human leukocyte 
antigen (HLA) both of which can be downregulated by tumors as a method of evading 
the immune system.20,21 
 The hinge region is also extracellular and serves to separate the binding domain 
from the transmembrane domain.19 The hinges are typically immunoglobulin-like and 
also provide stability to allow for efficient CAR expression and function.19 The 
transmembrane domain may be the least characterized aspect of the CAR with its primary 
role being to secure the CAR in the T cell membrane.19 However, there is some evidence 
suggesting that it may also have a pertinent role in the CAR T-cell function.19 
 The intracellular portion contains both a T-cell receptor signaling domain and a 
co-stimulatory domain.21 The costimulatory domain helps to regulate the survival and 
effector function of the T-cells.19 The costimulatory domains have distinct properties that 
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make it improbable that some costimulatory domain will serve all desired purposes.19 
Therefore, substantial research and understanding should be used when determining the 
best intracellular portion not only per disease, but also potentially per individual.  
 The function of the CAR when introduced to a T-cell is that the T-cell has greater 
antigen specificity and contains the signals necessary for full T-cell activation.19 Since the 
creation of CARs, there are now three distinct generations. These generations are 
distinguished by the number of costimulatory domains: the first generation contains 
CD3z only, the second generation contains one costimulatory domain and CD3z, and the 
third generation contains greater than one costimulatory domain along with CD3z.19 Both 
FDA approved CAR T-cell therapies to treat relapsed or refractory DLBCL, Yescarta, 
generic name axicabtagene ciloleucel, and Kymriah, generic name tisagenlecleucel, are 
second generation CARs.22–24  
 
Clinical Course of CAR T-cell Therapy 
The first step when considering CAR T-cell for a patient is determining if they are 
eligible to receive the therapy.25 This is determined based on a variety of tests and 
screenings and may vary slightly at different treatment centers.25 At Dana-Farber Cancer 
Institute (DFCI), where the research performed in this thesis was conducted, some of the 
eligibility criteria includes: having a confirmed diagnosis of DLBC, PMLBCL, HGBCL, 
or TFL, having failed at least two lines of chemotherapy or relapsed within twelve 
months of receiving an HD-ASCT, and lastly, having sufficient cardiac, pulmonary, and 
organ function.26 
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After a patient has been deemed eligible, the next step is collecting the T-cells. 
The T-cells are removed from the patient’s blood using a processed called apheresis 
where their blood is taken from the patient’s body, the targeted components, in this case 
T-cells, are removed, and the remaining blood is returned to the patient.25 Once collected, 
the T-cells are transported to a laboratory where they are genetically engineered to 
express CARs.25 Next, the CAR T-cells undergo multiplication in the laboratory until 
there are millions, which may take a few weeks, and then they are frozen and sent to the 
hospital where infusion takes place.25  
Prior to infusion, patients undergo a lymphodepletion regimen consisting of 
varying chemotherapies that remove immunosuppressive elements and create room 
within the patient’s immune system to allow for expansion and proliferation of the CAR 
T-cells.21,25 For both axicabtagene ciloleucel and tisagenlecleucel, the chemotherapy 
agents fludarabine and cyclophosphamide are used before infusion of the CAR T-
cells.18,27 The reasoning behind lymphodepletion before infusion is that it might increase 
the efficacy of the CAR T-cells by hampering the start of a T cell immune response 
against the murine single-chain variable fragment aspect of the CAR.21 After completing 
lymphodepletion, the patient is ready to undergo infusion of the CAR T-cells.  
The process of the CAR T-cell infusion is similar to a blood transfusion, however, 
patients are admitted for anywhere from a few days to several weeks in order to monitor 
and treat any side effects or complications that may occur as a result of the infusion.25 
These side effects will be discussed at length in the next section. Once the appropriate 
time has passed without any sign of complications, or complications have been resolved, 
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the patient is discharged and must remain close to the hospital for at least thirty days 
post-infusion due to the common need for readmission because of additional side effects. 
25  
 A clear protocol for long-term follow-up for patients who have received CAR T-
cell therapy has not been established due to the newness of the therapy and the variables 
of an individual patient’s response.21 It is recommended by the leading experts in CAR T-
cell therapy to use positron emission tomography (PET)/computed tomography (CT) to 
determine a patient’s response to treatment and, if further treatment is needed, decrease 
time to the next intervention.21 The intervals at which imaging occurs depends on 
treatment responses, but has been recommended for all patients at one month and three 
months post-infusion.21 For axicabtagene ciloleucel and tisagenlecleucel, disease 
progression or relapse is mostly seen within the first three to six months post-
infusion.21,28,29 Until further long-term data is collected, it is suggested that imaging for 
patients in CR after three months be done when deemed appropriate by the physician, 
whereas PET/CT imaging every three months is recommended for patients not in CR.21 
 
CAR T-cell Therapy Toxicities 
 CAR T-cell therapy is of great clinical value due to its ability to provide 
significant clinical responses, particularly in patients who may have previously been 
without effective later lines of therapy.30 However, it comes with a set of distinct 
toxicities that can range from mild to severe to sometimes fatal.30 These toxicities tend to 
be distinct from the toxicities seen in more traditional treatment options, such as 
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chemotherapy or monoclonal antibodies.30 One main mechanism that may be responsible 
for some of the toxicities is an on-target, off-tumor effect where the tumor associated 
antigen is also expressed on normal tissue that can then lead to tissue damage.30,31 
Additionally, CAR T-cells may unpredictably cross-react with proteins that are not found 
on the tumor cells and cause damage to non-cancerous tissue.31 Table 1 contains a 
comprehensive list of CAR T-cell toxicities. 
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Table 1. CAR T-cell Toxicities 
 
List of possible toxicities a patient may experience after receiving CAR T-cell therapy. Taken from Brudno 
JN and Kochenderfer JN, 2019 
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 The two most commonly occurring toxicities are cytokine release syndrome 
(CRS) and immune effector cell (IEC)-associated neurotoxicity syndrome (ICANS).30,32,33 
CRS is a systemic inflammatory response that is noted to cause high fevers, hypotension, 
hypoxia, and cardiac and other organ dysfunctions.32 CRS is believed to be caused by the 
release of cytokines from not only the infused CAR T-cells, but also from other immune 
cells, such as macrophages, that may produce cytokines in response to the cytokines 
produced by the CAR T-cells.30–32 In  ZUMA-1, the phase 2 clinical trial that led to the 
FDA approval of axicabtagene ciloleucel, 94% of patients had CRS.29 The rate of patients 
experiencing grade 3 or above CRS was 11% of axicabtagene ciloleucel  patients in the 
ZUMA-1 trial and 22% of tisagenlecleucel patients in the JULIET trial, the phase 2 
clinical trial that also lead to FDA approval.28,29  
Increased circulating interleukin (IL)-6 and interferon g.34 Tocilizumab, an anti-
IL-6  humanized monoclonal antibody, is used with or without corticosteroids to reverse 
CRS.34 Tocilizumab is considered the first line treatment for CRS due to its more rapid 
response.34 Corticosteroids are considered second line although they are an effective 
treatment option for CRS.34 This is because corticosteroids can suppress T-cell function 
and induce apoptosis.30   
 ICANS is characterized as a toxic encephalopathic state that leads to symptoms of 
confusion, delirium, seizures ,and cerebral edema.30 However, ICANS has diverse 
presentations and does not target any one specific area in the central nervous system.31,32 
Other commonly seen effects of ICANS include but are not limited to headaches, 
confusion, somnolence, hallucinations, dysphasia, ataxia, apraxia, tremors, and seizures.32 
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Publications note the rate of ICANS as being anywhere from 0% to 50%. 31 The rate of 
grade 3 and 4 ICANS for axicabtagene ciloleucel patients in the ZUMA-1 study is 32% 
and 12% for tisagenlecleucel patients in the JULIET trial.28,29 Corticosteroids are used in 
the treatment of ICANS.30 
 
Prolonged Cytopenias in CAR T-cell Therapy Patients 
 Another common group of toxicity seen in CAR T-cell patients is hematopoietic 
toxicities including neutropenia, anemia, and thrombocytopenia.35 More commonly 
referred to as cytopenias, some studies suggest that upwards of 90% of patients 
experience cytopenia after CAR T-cell infusion.21 The United States Department of 
Health and Human Services publishes a Common Terminology Criteria for Adverse 
Events (CTCAE) that helps standardize adverse event (AE) reporting.36 Each AE is 
graded from one to five with one being mild and five meaning death occurred relating to 
the AE.36 Table 2 provides the definition of the cytopenias along with the CTCAE criteria 
for grading each cytopenia.36  
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Table 2. Cytopenia Definitions and Grading based on CTCAE Criteria 
CTCAE Term Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Anemia Hemoglobin 











Definition: A disorder characterized by a reduction in the amount of hemoglobin in 100 ml of blood. 
Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of 










ANC <500/mm3 N/A 
Definition: A finding based on laboratory test results that indicate a decrease in number of 









PLT <25,000/mm3 N/A 
Definition: A finding based on laboratory test results that indicate a decrease in number of platelets 
in a blood specimen 
LLN: Lower Limit of Normal 
Adapted from Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, 2017 
 
Cytopenias typically occur within the first 28 days after infusion, but may take 
three months or more to improve.21 Identifying the cause of these cytopenias is a 
challenge because they could be an effect of heavy pretreatment, the cytotoxic 
lymphodepletion regimens, an overall effect of CAR-Ts, or a combination of the three.21 
With the understanding that the chemotherapy used during lymphodepletion is known to 
cause cytopenias, it is important to note that patients who did not receive 
lymphodepleting chemotherapy have also had cytopenias shows that there is some 
mechanism of caused by the CAR T-cells that leads to myelosuppression.31 Neutropenia 
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is the most common type, affecting more than 81%-94% of patients (Table 2).21,28,29 
Thrombocytopenia is the second most common type, affecting between 54%-80% and 
anemia affecting 51%-66% (Table 2).21,28,29 Cytopenias are typically managed by 
administering growth factors or through transfusions.21,31 However, what is possibly more 
concerning are prolonged cytopenias.  
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The definition for prolonged cytopenias differs slightly in regard to time since 
infusion, but it generally refers to cytopenias lasting more than 28-42 days post-
infusion.37–39 Data from the ZUMA-1 study and the JULIET study show the rates of 
prolonged cytopenias respectively being 26% and 24% for neutropenia, 24% and 41% for 
thrombopenia, and 10% for anemia in the ZUMA-1 study with no data for prolonged 
anemia in the JULIET study (Table 2).21,28,29 Prolonged cytopenias have been associated 
with many factors including CRS severity, tumor burden, number of prior therapies, and 
prior HD-ASCT or allogenic transplants.21   
One study conducted by Nahas and colleagues sought out to identify potential risk 
factors associated with prolonged cytopenias.38 They investigated the number of prior 
chemotherapy regimens, ANC and PLT counts on the first day of lymphodepletion, CRS 
grade 3 and above, baseline CRP, ferritin and CRP peak after infusion, and time from 
infusion to maximum grade CRS as possible predictive factors.38 They reported two 
significant findings: a thrombocytopenia of ≤ 75,000/microliter on the first day of 
lymphodepletion and the median time of less than one day to reach maximum CRS post-
infusion.38 It is worth noting that this study included the analysis of twenty-two patients, 







• Identify clinical predictors along with pretreatment patient and disease precursors that 
increase risk of experiencing prolonged cytopenias after CAR T-cell therapy. 
• Analyze the difference in patients with and without prolonged cytopenias in regard to 





Study Population and Eligibility  
 This study was a retrospective analysis of patients who received commercial CAR 
T-cell therapy at DFCI, either axicabtagene ciloleucel or tisagenlecleucel, from 
December 2017 to September 2019. Protocols that allow for retrospective analysis were 
approved by DFCI’s Institutional Review Board (IRB). There were 106 commercial CAR 
T-cell recipients consented to these protocols during this period of time. More specific 
criteria were used to delineate the portion of this population that experienced prolonged 
cytopenias.  
 For our prolonged cytopenic cohort, we required that the patients must be alive at 
least three months post-infusion and have blood work for at least two of the following 
three timepoints: one-, three-, or six-months post-infusion. We examined Hgb, ANC, and 
PLT counts for one month, three months, and six months post-infusion, as available per 
each patient. We considered cytopenic values as Hgb <10 g/dL, grade 2 per CTCAE 
criteria, PLT < 50,000/mm3, and ANC <1000/mm3, both grade 3 per CTCAE criteria 
(Table 2).36 For a patients to be considered to have prolonged cytopenias, they must either 
have more than 1 time point post-infusion where cytopenic values were recorded for the 
same type of cytopenia(s). If they only have one timepoint where a cytopenic value was 
recorded, they must have received a transfusion of red blood cells (RBC) or platelets or 
received granulocyte-colony stimulating factor (GCSF) after their last cytopenic value 
since this could be the cause for the recovery of their cytopenic counts. Figure 1 visually 
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shows the schema for selecting our cytopenic population. These criteria identified 22 
patients that matched our definition of having prolonged cytopenias.  
 
Figure 1: Patient Selection Criteria Flow Chart 
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Falling outside the criteria for prolonged cytopenias were 84 patients. The 
requirement for being considered part of the non-cytopenic, commercial CAR T-cell 
cohort was that the patients must have been infused with commercial CAR T-cells. There 




  Through retrospective review of patient medical records, we recorded data 
involving potential predictors of prolonged cytopenias, incidences of AE and if they 
required intervention, response rates to therapy from PET/CT scans, and various 
laboratory values, mainly collected from blood samples, from pre- and post-infusion. A 
full list of variables collected can be found in Appendix I. The Eastern Cooperative 
Oncology Group (ECOG) Performance Status was used to note a patient’s level of 
function before undergoing CAR T-cell therapy. To examine if prognostic values had any 
relation to experiencing prolonged cytopenias, the International Prognostic Index (IPI) 
was collected for patients pre-lymphodepletion. In regard to PET/CT scans, the Deauville 
criteria and the Lugano staging and response classifications were used to determine status 
of disease prior to CAR T-cell therapy as well as the response post-infusion. CRS was 
graded based on the Lee criteria and ICANS was graded based on CTCAE criteria. All of 
the aforementioned grading methods’ criteria can be found in Appendix II.  
 In order to consider additional factors involved when a patient has AEs, we also 
collected data for tocilizumab and steroid administration during the patients’ hospital 
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admissions. We noted if the patient received any of these medications and then further 
grouped patients by the number of doses received. For analysis of tocilizumab, we 
separated patients into two groups: those that had only one dose and those who had two 
or more. For steroids, we also had two groups: patients who had four or less doses of 
steroids and patients who had five or more.   
 
Statistical Analysis 
 Patient characteristics were reported with summary statistics for the overall cohort 
and by group (cytopenic versus non-cytopenic). Continuous, nominal, and ordinal 
variables were tested for association by group using Wilcoxon rank-sum, Fisher’s exact, 
and Kruskal-Wallis trend tests, respectively. Patient responses were summarized as 
proportions with 95% exact binomial confidence intervals (CI). Overall survival (OS) 
was measured from date of infusion until death from any cause; patients alive at data 
collection were censored at last contact for OS. Progression-free survival was measured 
from date of infusion until progression or death from any cause; patients alive and 
progression-free at data collection were censored at last contact for PFS. Survival 
distributions by group were estimated using the Kaplan-Meier method, and differences 
between groups were assessed with log-rank tests. Uni- and multi-variable logistic 
regressions were performed using Firth’s bias-reduced penalized likelihood method due 
to a small number of cytopenic patients. Logistic models were summarized as odds ratios 
(OR) with CIs and p-values based on the penalized log-likelihood. Multivariable model 
selection was performed using a forward/backward stepwise variable selection procedure 
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based on a penalized likelihood ratio test. Naïve and corrected p-values for univariable 
analyses were calculated; where indicated p-value adjustments for multiple tested was 
performed using the Benjamini-Hochberg method. All analyses were performed using R 




Patient Characteristics and Outcomes 
There were 106 patients who received commercial CAR T-cell therapy included 
in the study. The median age was 62 (range: 19 – 80) years old. 67 patients had de novo 
aggressive B-cell NHL while 39 had transformed aggressive B-cell NHL. 32% had 
previously been treated with HD-ASCT. The median number of prior treatment regimens 
was 3 (range: 2 - 9). The median time with aggressive B-cell NHL until day of infusion 
was 11.6 months. Additionally, the median time since last chemotherapy regimen before 
CAR T-cell infusion was 3.1 months. 81% (95% CI: 72 – 88%) of patients achieved and 
overall response rate of either CR or partial response (PR), while 19% had a best overall 
response of either stable disease (SD) or progressive disease (PD). In terms of best CR 
rate, 64 (60%, 95% CI: 50 – 70%) patients achieved CR while 42 had the best response 
of either PR, SD, or PD. Data regarding the aforementioned patient characteristics is 
presented in table 4 and is further separated into cytopenic and non-cytopenic cohorts.  
The length of time from diagnosis of aggressive B-cell NHL to date of CAR T-
cell infusion was found to be positively corelated with an increased risk of developing 
prolonged cytopenias after CAR T-cell therapy. For the cytopenic population, the median 
time from diagnosis of aggressive B-cell lymphoma to CAR T-cell infusion was 15.2 
months, whereas the non-cytopenic population’s median time was 10.3 months (Table 4).  
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Table 4. Patient Characteristics 
 
      Cohort     
 Total  Cytopenic Non-cytopenic  p-value 
n = 106 (%) n = 22 (21) n = 84 (79) 
Age at infusion 
  Median (range) 62 (19 - 80)  64 (43 - 73) 62 (19 - 80)  0.71† 
Diagnosis 
  Transformed 39 (37)  9 (41) 30 (36)  0.80‡ 
  de novo 67 (63)  13 (59) 54 (64)   
Stage at diagnosis 
  1 14 (13)  2 (9) 12 (14)  0.63§ 
  2 10 (9)  2 (9) 8 (10)   
  3 33 (31)  10 (45) 23 (27)   
  4 49 (46)  8 (36) 41 (49)   
ECOG 
  0 38 (36)  6 (27) 32 (38)  0.29§ 
  1 54 (51)  11 (50) 43 (51)   
  2 8 (8)  2 (9) 6 (7)   
  3 1 (1)  1 (5) -   
  Missing 5 (5)  2 (9) 3 (4)   
IPI (pre-lymphodepletion) 
  0 9 (8)  1 (5) 8 (10)  0.74§ 
  1 20 (19)  4 (18) 16 (19)   
  2 26 (25)  8 (36) 18 (21)   
  3 25 (24)  4 (18) 21 (25)   
  4 17 (16)  2 (9) 15 (18)   
  5 3 (3)  1 (5) 2 (2)   
  Missing 6 (6)  2 (9) 4 (5)   
Prior auto transplant 
  Yes 34 (32)  7 (32) 27 (32)  > 0.99‡ 
  No 72 (68)  15 (68) 57 (68)   
Number of prior treatment regimens 
  Median (range) 3 (2 - 9)  3 (2 - 9) 3 (2 - 8)  0.56‡ 
Bone Marrow Involvement 
  Yes 15 (14)  3 (14) 12 (14)  > 0.99‡ 
  No 91 (86)  19 (86) 72 (86)   
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Table 4. Patient Characteristics (continued) 
 
      Cohort     
 Total  Cytopenic Non-cytopenic  p-value 
n = 106 (%) n = 22 (21) n = 84 (79) 
 
Time with aggressive lymphoma diagnosis (months) 
  Median (range) 11.6 (3.7 - 25.8)  15.2 (8.0 - 24.5) 10.3 (3.7 - 25.8)  0.011† 
Time since last chemotherapy before CAR T-cell infusion (months) 
  Median (range) 3.1 (1.1 - 197.5)  3.7 (1.4 - 197.5) 3.0 (1.1 - 139.5)  0.73† 
Time between leukapheresis and infusion (days) 
  Median (range) 26 (5 - 70)  27 (22 - 53) 26 (5 - 70)  0.29† 
Best overall response rate 
  CR/PR 86 (81)  21 (95) 65 (77)  0.067‡ 
  SD/PD 20 (19)  1 (5) 19 (23)   
Best complete response rate 
  CR 64 (60)  15 (68) 49 (58)  0.47‡ 
  PR/SD/PD 42 (40)   7 (32) 35 (42)     
†Wilcoxon rank-sum test, ‡Fisher's exact test, §Kruskal-Wallis trend test 
 
 
Cytopenic Population Characteristics  
 Of the 22 patients in the cytopenic cohort, 8 had only one type of cytopenia, 9 had 
two types, and 5 had all three types of cytopenia (Figure 2). In total, there were 16 
patients with prolonged anemia, 13 patients with prolonged thrombocytopenia, and 12 
patients with neutropenia (Figure 3). For the 9 patients that had two types of cytopenias, 
5 has anemia and thrombocytopenia, 2 had neutropenia and thrombocytopenia, and 2 had 
anemia and neutropenia (Figure 4).  
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Figure 4: Frequency of Cytopenia Combinations in Patients with Two Types of 
Prolonged Cytopenias 
 
Four of the 22 patients underwent radiation therapy before leukapheresis for CAR 
T-cell therapy. Of these four patients, one had radiation to the left upper quadrant of the 
abdomen, one to the mediastinum, and two to the breast. Furthermore, seven patients had 
bone marrow biopsies done post-infusion of CAR T-cell. One patient was found to have 
Myelodysplastic Syndrome (MDS) (Table 5). All patients were found to have 
hypocellular marrow and furthermore, all had decreased myeloid cell lines (Table 5). 5 of 
the 7 patients had decreased megakaryocyte cell lines while the other 2 patients’ 
megakaryocyte cell lines were normal (Table 5). The most variation was seen in the 
erythroid cell line with 3 patients having an increase, 3 having a decrease, and one patient 







































































 Although we found that the number of prior lines of therapy a patient had 
received prior to CAR T-cell infusion was not a predictive factor of prolonged 
cytopenias, we further investigated to see if any individual regimens were predictive. To 
explore this, we analyzed the rate of all chemotherapy used throughout the course of a 
patient’s treatment as well as what chemotherapy regimens were used prior to CAR T-
cell infusion.  
 When investigating all chemotherapy regimens administered prior to apheresis, 
the two most common in both cohorts were RCHOP and RICE (Table 6). This is not 
surprising considering RCHOP is the standard first line therapy for patients with 
aggressive B-cell NHL and RICE is a common salvage therapy option. Both RICE and 
lenalidomide were found to be administered at higher rates in the cytopenic cohort upon 
naïve Fisher’s analysis (Table 6). However, when corrected using the BH procedure, 
neither of these retained their significance. 
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Fisher's exact p 
(naïve) 
R-CHOP 18∗ 71‡ 0.75 
RICE 18* 48 0.047 
R-GDP 5 19§ > 0.99 
BR 4 12 0.74 
R-GemOx 4 7* 0.23 
Lenalidomide 3 0 0.008 
R-EPOCH 2 21¶ 0.15 
R-DHAC 2† 4 0.6 
R-ESHAP 0 4* 0.58 
R-CVP 2 3 0.28 
R-DHAP 0 3* > 0.99 
OCHOP 0 3 > 0.99 
Idelesib 1 3 > 0.99 
Selinexor 0 2 > 0.99 
M-BACOP 0 2 > 0.99 
R-VIC 0 2 > 0.99 
Venetoclax 0 2 > 0.99 
Cisplatin 0 2 > 0.99 
*: 1 patient did not receive rituximab; †: 1 patient also receive ifosfamide; ‡: 3 patients did not receive 
rituximab; §: 2 patients did not receive rituximab; ¶: 4 patients received an adjusted dose;  
Abbreviations: BR: bendamustine, rituximab; M-BACOP: methotrexate, bleomycin, doxorubicin, 
cyclophosphamide, prednisone; O-CHOP: obinutuzumab, cyclophosphamide, doxorubicin, 
vincristine, prednisone; R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; 
R-CVP rituximab, cyclophosphamide, vincristine, prednisone; R-cytarabine: rituximab, cytarabine; R-
DHAC rituximab, dexamethasone, cytarabine, carboplatin; R-DHAP rituximab, dexamethasone, 
cytarabine, cisplatin; R-EPOCH rituximab, etoposide, prednisone, vincristine, cyclophosphamide, 
docorubicin; R-ESHAP rituximab, etoposide, solu-medrone, cytarabine, cisplatin; R-GDP: rituximab, 
gemcitabine, dexamethasone, cisplatin; R-gem/navelbine: rituximab, gemcitabine, navelbine; R-
GemOx: rituximab, gemcitabine, oxaliplatin; RICE: rituximab, ifosfamide, carboplatin, etoposide; R-
VIC: rituximab, etoposide, ifosfamide, carboplatin 




We examined the last chemotherapy regimens used before apheresis. RICE was 
the most common in both cohorts (Table 7). Out of all the regimens analyzed, R-
cytarabine was the only one to be associated with an increased risk of prolonged 
cytopenias based on a naïve Fisher’s exact test (Table 7). However, this finding did not 
hold up to BH correction.  
 
Table 7. Frequency of Last Used Chemotherapy Regimens Before Lymphodepletion 
 
Chemotherapy Regimen Cytopenic Non-Cytopenic 
Fisher's exact 
p (naïve) 
RICE 8* 28 0.8 
R-GDP 3 8 0.69 
BEAM 3 10 0.73 
R-GemOx 2 8* > 0.99 
R-cytarabine 2 0 0.042 
R-GDC 1 2* 0.51 
R-CHOP 1 2 0.51 
BR 1 2† 0.51 
R-gem/navelbine 1 0 0.21 
R-DHAP 0 3* > 0.99 
R-EPOCH 0 3‡ > 0.99 
R-DHAC 0 3 > 0.99 
O-CHOP 0 2§ > 0.99 
Unlituximab, bendamustine, umbralisib 0 2 > 0.99 
Selinexor clinical trial 0 2 > 0.99 
*: 1 patient received regimen without rituximab (R); †: 2 patients received regimen with polatuzumab; 
and ibrutinib with regimen, ‡: 1 patient received regimen at an adjusted dose; §: 1 patient received 
venetoclax 
Abbreviations: BEAM: carmustine, etoposide, cytarabine, melphalan; BR: bendamustine, rituximab; 
O-CHOP: obinutuzumab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-CHOP: 
rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-cytarabine: rituximab, 
cytarabine; R-DHAC rituximab, dexamethasone, cytarabine, carboplatin; R-DHAP rituximab, 
dexamethasone, cytarabine, cisplatin; R-EPOCH rituximab, etoposide, prednisone, vincristine, 
cyclophosphamide, doxorubicin; R-GDP: rituximab, gemcitabine, dexamethasone, cisplatin; R-
gem/navelbine: rituximab, gemcitabine, navelbine; R-GemOx: rituximab, gemcitabine, oxaliplatin; 
RICE: rituximab, ifosfamide, carboplatin, etoposide; R-VIC: rituximab, etoposide, ifosfamide, 
carboplatin 
Includes any chemotherapy regimen administered to at least 2 patients in at least one of the cohorts. 
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Laboratory Results 
 We collected data on eight different laboratory tests of interest at varying time 
points totaling to 19 different values of interest (Table 8). Of these 19, lower values of 
ANC on day 0, PLT on day 0, and Hgb pre-apheresis and on day 0 were all associated 
with an increased risk of prolonged cytopenia (Table 8). Additionally, higher values of 
CRP pre-lymphodepletion and on day 0 were associated with an increased risk of 
prolonged cytopenia (Table 8).  
 
Table 8. Laboratory Results 
      Cohort     
 Total  Cytopenic Non-cytopenic  p-value 
n = 106 (%) n = 22 (21) n = 84 (79)  
ANC pre-leukapheresis 
  Median 
(range) 3560 (460 - 71600) 
 2895 (1420 - 6240) 3780 (460 - 71600)  0.077† 
  Missing 2 (2)  0 (0) 2 (2)   
ANC day 0 
  Median 
(range) 3485 (90 - 99000) 
 1530 (290 - 6890) 3960 (90 - 99000)  < 0.001† 
  Missing 4 (4)  1 (5) 3 (4)   
   
CRP pre-lymphodepletion 
  Median 
(range) 10.1 (0.3 - 190.6) 
 17.8 (1.0 - 190.6) 8.4 (0.3 - 187.3)  0.034† 
  Missing 2 (2)  2 (9) 0 (0)   
CRP day 0 
  Median 
(range) 21.2 (2.8 - 300.0) 
 41.1 (7.6 - 300.0) 18.5 (2.8 - 300.0)  0.045† 
  Missing 4 (4)  0 (0) 4 (5)   
CRP max post-CARs 
  Median 
(range) 98.5 (4.8 - 300.0) 
 141.6 (28.9 - 300.0) 91.5 (4.8 - 300.0)  0.12† 
 
LDH pre-lymphodepletion 
  Median 
(range) 212 (85 - 1722) 
 258 (85 - 959) 208 (109 - 1722)  0.44† 
LDH day 0 
  Median 
(range) 242.0 (109.5 - 2150.0) 
 280.0 (170.0 - 1931.0) 236.0 (109.5 - 2150.0)  0.16† 
  Missing 1 (1)  0 (0) 1 (1)   
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Table 8.  Laboratory Results (continued) 
 
      Cohort     
 Total  Cytopenic Non-cytopenic  p-value 
n = 106 (%) n = 22 (21) n = 84 (79) 
    
Ferritin pre-lymphodepletion 
  Median 
(range) 851 (107 - 7965) 
 888 (267 - 3466) 776 (107 - 7965)  0.33† 
  Missing 81 (76)  13 (59) 68 (81)   
Ferritin day 0 
  Median 
(range) 716 (75 - 20003) 
 1205 (249 - 7846) 667 (75 - 20003)  0.076† 
  Missing 6 (6)  1 (5) 5 (6)   
Ferritin max post-CARs 
  Median 
(range) 1612 (48 - 61104) 
 2321 (476 - 27505) 1482 (48 - 61104)  0.097† 
  Missing 9 (8)  1 (5) 8 (10)   
 
ALC at leukapheresis 
  Median 
(range) 595 (90 - 7600) 
 530 (90 - 1880) 605 (90 - 7600)  0.67† 
ALC max post-CARs 
  Median 
(range) 720 (20 - 12650) 
 710 (100 - 3780) 735 (20 - 12650)  0.80† 
ALC at max grade CRS 
  Median 
(range) 70 (0 - 11330) 
 60 (10 - 1180) 80 (0 - 11330)  0.79† 
  Missing 36 (34)  7 (32) 29 (35)   
       
IL-6 day 0 
  Median 
(range) 4.9 (1.2 - 88.6) 
 8.1 (1.3 - 43.6) 4.8 (1.2 - 88.6)  0.29† 
  Missing 27 (25)  7 (32) 20 (24)   
IL-6 max 
  Median 
(range) 160.0 (5.7 - 400.0) 
 400.0 (5.9 - 400.0) 113.5 (5.7 - 400.0)  0.065† 
  Missing 25 (24)  7 (32) 18 (21)   
        
Platelets pre-leukapheresis 
  Median 
(range) 164 (28 - 503) 
 126 (28 - 421) 171 (40 - 503)  0.079† 
  Missing 2 (2)  0 (0) 2 (2)   
Platelets day 0 
  Median 
(range) 99 (7 - 311) 
 60 (7 - 311) 105 (12 - 305)  0.007† 
  Missing 2 (2)  0 (0) 2 (2)   
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Table 8.  Laboratory Results (continued) 
 
      Cohort     
 Total  Cytopenic Non-cytopenic  p-value 
n = 106 (%) n = 22 (21) n = 84 (79) 
    
         
Hemoglobin pre-leukapheresis 
  Median 
(range) 10.6 (6.6 - 14.5) 
 9.8 (6.6 - 12.6) 11.1 (7.2 - 14.5)  0.006† 
  Missing 2 (2)  0 (0) 2 (2)   
Hemoglobin day 0 
  Median 
(range) 9.50 (3.11 - 13.30) 
 8.65 (6.20 - 11.60) 9.90 (3.11 - 13.30)  0.005† 
  Missing 2 (2)   0 (0) 2 (2)     
†Wilcoxon rank-sum test 
Abbreviations: ANC: absolute neutrophil count; CRP: C-reactive protein; LDH: lactate dehydrogenase; 
ALC: absolute lymphocyte count; IL-6: interleukin-6 
 
To further understand which of these variables are most associated with increased 
risk of prolonged cytopenias, we performed an additional univariate analysis to the 
results of Table 8. This allowed us to not only see which values correlated with either 
cohort, but also the degree of association the individual results had with the cohorts.  This 
analysis determined that higher values for Hgb pre-leukapheresis and on day 0 are 
associated with not having prolonged cytopenias (Figure 5).  
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Figure 5: Volcano Plot of Laboratory Values 
Abbreviations: ANC: absolute neutrophil count; CRP: C-reactive protein; IL-6: interleukin-6 
Visual representation of univariate analysis of laboratory values. Data points with a negative odds 
ratio represents that higher value of those laboratory test are associated with non-cytopenic patients. 
Conversely, data points with a positive odds ratio are associated with having higher values being 
found in cytopenic patients. 
 
Furthermore, a multivariable analysis was also conducted on the laboratory values 
to determine which values maintained their significance in comparison to the other 
values. Three values were determined to remain significant (Figure 6). Cytopenic patients 
had significantly higher CRP values pre-lymphodepletion than non-cytopenic patients 
(Figure 6). Meanwhile, patients without prolonged cytopenias were more likely to have a 
higher ferritin and PLT values on day 0 (Figure 6). 



































Figure 6: Forest Plot of Laboratory Values 
Abbreviation: CRP: C-reactive protein. Visual representation of the multivariate analysis of laboratory 
values. Odds ratio of less than one suggests higher laboratory values are more likely to be observed in 
non-cytopenic patients. Meanwhile, odds ratio of greater than one would suggest higher laboratory 
values would be found in cytopenic patients.  
 
Adverse Events and Related Interventions 
 87% of all patients in the study experienced CRS with 8% having max grade 3 or 
higher (Table 9). Moreover, 45% of patients had max grade 2 CRS and 34% had max 
grade 1 CRS (Table 9). The median duration of CRS was 6 days with time to max CRS 
being 4 days (Table 9). The distribution of max CRS grade for cytopenic and non-
cytopenic patients was not statistically different (Figure 7). Furthermore, 61% of all 
patients had some severity of ICANS with 34% having grade 3 or higher (Table 9). 
Similar to CRS, the distribution of max ICANS grading was not statistically different 
between the cytopenic and non-cytopenic cohorts (Figure 8). When comparing cytopenic 
and non-cytopenic cohorts in regards of incidence of CRS and ICANS, there was no 
statistically significant association with either cohort (Table 9). 
CRP pre−lymphodepletion
  10−unit increase
Ferritin day 0
  1000−unit increase
Platelets day 0











OR (95% CI) p−value
0.0 0.5 1.0 1.5 2.0
Odds ratioNon−cytopenic Cytopenic
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Table 9. Adverse Events Prevalence, Severity, and Duration 
 
      Cohort     
 Total  Cytopenic Non-cytopenic  p-value n = 106 (%) n = 22 (21) n = 84 (79) 
Max grade CRS 
  0 13 (12)  2 (9) 11 (13)  0.50§ 
  1 36 (34)  7 (32) 29 (35)   
  2 48 (45)  11 (50) 37 (44)   
  3 4 (4)  1 (5) 3 (4)   
  4 3 (3)  1 (5) 2 (2)   
  5 1 (1)  - 1 (1)   
  Missing 1 (1)  0 (0) 1 (1)   
CRS grade ≥ 2 
  Yes 56 (53)  13 (59) 43 (51)  0.63‡ 
  No 49 (46)  9 (41) 40 (48)   
  Missing 1 (1)  0 (0) 1 (1)   
Duration of CRS (any grade) 
  Median 
(range) 6 (0 - 20) 
 6 (0 - 15) 6 (0 - 20)  0.40† 
  Missing 12 (11)  1 (5) 11 (13)   
Time to max CRS 
  Median 
(range) 4 (0 - 12) 
 4 (0 - 10) 4 (0 - 12)  0.21† 
  Missing 14 (13)  2 (9) 12 (14)   
Time to grade 2+ CRS 
  Median 
(range) 4 (0 - 12) 
 4 (0 - 10) 4 (0 - 12)  0.41† 
  Missing 50 (47)  9 (41) 41 (49)   
Max grade ICANS 
  0 40 (38)  6 (27) 34 (40)  0.49§ 
  1 16 (15)  4 (18) 12 (14)   
  2 13 (12)  4 (18) 9 (11)   
  3 12 (11)  3 (14) 9 (11)   
  3a 19 (18)  5 (23) 14 (17)   
  3b 5 (5)  - 5 (6)   
  Missing 1 (1)  0 (0) 1 (1)   
ICANS grade ≥ 2 
  Yes 49 (46)  12 (55) 37 (44)  0.47‡ 
  No 56 (53)  10 (45) 46 (55)   
  Missing 1 (1)   0 (0) 1 (1)     





Figure 7: Distribution of CRS in Cytopenic and Non-cytopenic Cohorts 
Abbreviation: CRS: Cytokine Release Syndrome 
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Figure 8: Distribution of ICANS in Cytopenic and Non-cytopenic Cohorts 
Abbreviation: ICANS: IEC-Associated Neurotoxicity Syndrome 
 
When examining tocilizumab and steroid administration, we found that 68 
patients received tocilizumab. Of those 68 patients, 26 received one dose of tocilizumab 
while 42 patients were given two or more doses. Steroids were administered for CRS 
management to 40 patients while they were administered for ICANS management to 41 
patients. When considering total steroid administration, 26 patients received four or less 
doses of steroids, whereas 30 patients received five or more doses. No statistical 
significance was found regarding differences in tocilizumab or steroid administration 
between cytopenic and non-cytopenic cohorts. Data regarding tocilizumab and steroid 





Table 10. Tocilizumab and Steroid Administration for CRS and ICANS 






n = 106 (%) n = 22 (21) n = 84 (79) 
Tocilizumab administered 
  Yes 68 (64) 
 
16 (73) 52 (62) 
 
0.46‡ 
  No 38 (36) 
 
6 (27) 32 (38) 
  
Steroids administered for CRS 
  Yes 40 (38) 
 
7 (32) 33 (39) 
 
0.62‡ 
  No 66 (62) 
 
15 (68) 51 (61) 
  
Steroids administered for ICANS 
  Yes 41 (39) 
 
10 (45) 31 (37) 
 
0.47‡ 
  No 65 (61) 
 
12 (55) 53 (63) 
  
Doses of tocilizumab 
  2+ 42 (40) 
 
12 (55) 30 (36) 
 
0.25‡ 
  1 26 (25) 
 
4 (18) 22 (26) 
  
  Missing 38 (36) 
 
6 (27) 32 (38) 
  
Doses of steroids (for CRS or ICANS) 
  5+ 30 (28) 
 
6 (27) 24 (29) 
 
> 0.99‡ 
  1-4 26 (25) 
 
6 (27) 20 (24) 
  
  Missing 50 (47)   10 (45) 40 (48)     
‡Fisher's exact test 
Abbreviations: CRS: Cytokine Release Syndrome; ICANS: IEC-Associated Neurotoxicity Syndrome 
 
 
Nine of the 22 patients in the cytopenic cohort experienced infections post-CAR 
T-cell infusion (Table 11). Thrush affected four patients, three patients had pneumonia, 
while upper respiratory infection (URI) and septic shock both affected two patients 
(Table 11). Also, several infections were only found to affect one patient each: 
necrotizing soft tissue infection, central line associated blood stream infection, and 






Table 11. Infections of Cytopenic Cohort 
 
Patient # Infection(s) 
6 Septic shock, necrotizing soft tissue infection of right leg 
10 Upper respiratory infection 
19 Pneumonia, thrush 
24 Pneumonia, thrush 
29 Pneumonia 
43 Central line associated blood stream infection, thrush 
48 Thrush, upper respiratory infection 
69 Septic shock due to MRSA pneumonia in setting of neutropenia 
70 Urinary tract infection 
Abbreviation: MRSA: Methicillin-resistant Staphylococcus aureus 




 In the non-cytopenic cohort, 25 of the 84 patients had an infectious complication 
after receiving CAR T-cells (Table 12). When comparing the two cohorts, there was no 
difference in the incidence of infections (Table 12).  
 
Table 12. Incidence of Infections 
  
# of patients who had post-infusion 







Cytopenic 9 22 0.32 
Non-cytopenic 25 84  
Comparison of the incidence of infections between cohorts after CAR T-cell infusion 
Overall and Progression-free Survival 
 In order to investigate if having prolonged cytopenias affect a patient’s response 
to CAR T-cell therapy, we analyzed the PFS and OS rates of the cytopenic and non-
cytopenic cohorts (Figure 9). In terms of OS, at 12 months post-infusion the cytopenic 
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cohort had an OS of 68% (95% CI: 48 - 97) while the non-cytopenic cohort had an OS of 
64% (95% CI: 50 - 82) (Figure 9). Overall, there was no significant difference in OS 
between the two cohorts (Figure 9).  
 
 
Figure 9: Overall Survival of and Cytopenic and Non-cytopenic Cohorts 
Each hash mark represents a death of a patient 
  
  
At 12 months the cytopenic cohort had a PFS rate of 38% (95% CI: 21 - 69) 
whereas the non-cytopenic cohort had a PFS rate of 46% (95% CI:  33 - 64) (Figure 10). 




Figure 10: Progression Free Survival of Cytopenic and Non-cytopenic Cohorts 





 CAR T-cell therapy has given patients who formerly had few effective salvage 
treatment options an option that could potentially prove curative. However, CAR T-cell 
therapy comes with its own challenges including many well documented toxicities. While 
CRS and ICANS have been the focus of most investigations, there is a lack of 
understanding around hematologic toxicities. This study set out to identify possible 
clinical predictors and patient and disease precursors of prolonged cytopenias in order to 
better identify patients who are at risk of developing prolonged cytopenias.  
 Through this retrospective analysis of patients infused with commercial CAR T-
cells, we found several statistically significant differences between the cytopenic and 
non-cytopenic cohort. The first of these being the length of time with an aggressive B-
cell NHL diagnosis in relation to the day of CAR T-cell infusion. A longer time between 
diagnosis and CAR T-cell infusion was found to be associated with prolonged 
cytopenias. This is particularly interesting considering that the number of prior therapies 
a patient had prior to CAR T-cell therapy and if a patient had undergone an HD-ASCT 
were both found to not be associated with prolonged cytopenias. Due to these not 
providing any additional insight on why an increased length of time from diagnosis to 
CAR T-cell treatment is associated with prolonged cytopenias, it would be valuable for 
further investigations to examine what specifically about the length of time creates the 
association.  
 Our results regarding bone marrow biopsies were limited due to only having 
seven of the 22 cytopenic patients having had bone marrow biopsies after undergoing 
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CAR T-cell therapy. Furthermore, we were limited to PET/CT results for knowing if 
patients had disease involvement in their bone marrow before CAR T-cell therapy. It is 
concerning that all 7 patients did have hypocellular marrow and decrease myeloid cell 
lines. However, it would be beneficial to have a larger sample size with bone marrow 
biopsies from before and after CAR T-cell therapy to better investigate what effects CAR 
T-cell therapy has on a patient’s bone marrow compared to prior treatments or additional 
factors.  
 Through the analysis of laboratory values, we found that low ANC, PLT, and 
HGB on the day of infusion of CAR T-cells as well as low Hgb before leukapheresis 
were all associated with prolonged cytopenias. These findings suggest that patients with 
less bone marrow reserve were more likely to have prolonged cytopenias. This could 
mean that the patients who had prolonged cytopenias may have a weakened bone marrow 
before CAR T-cell therapy, possibly related to prior therapies. This further supports the 
need to examine patients’ bone marrow before and after CAR T-cell therapy.  
 High CRP values before lymphodepletion and on the day of CAR T-cell infusion 
were found to be associated with prolonged cytopenias. This could be reflective of 
something specific to their disease biology that could be a factor in developing prolonged 
cytopenias. Another possible explanation could be that their CAR T-cell expansion 
and/or persistence may be a factor due to higher pretreatment inflammation being related 
to increased CAR expansion. If this is the case, the prolonged cytopenias experienced 
would be an effect of CAR T-cell themselves and not of other previous treatments. 
Further investigation into the patients’ disease cytogentics would help to understand if 
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specific biological aspects of aggressive B-cell NHL are associated with prolonged 
cytopenias.  
 Using multivariable analysis, high CRP values prior to lymphodepletion and on 
day of CAR T-cell infusion were found to be the most predictive results associated with 
patients experiencing prolonged cytopenias. It would be valuable for additional studies to 
investigate if these values are associated with prolonged cytopenias. Therefore, if found 
to be associated in larger population of patients, these values could be used by physicians 
to indicate an increased risk of a patient developing prolonged cytopenias. Conversely, 
high ferritin and PLT on the day of infusion were found to be associated with not having 
prolonged cytopenias. If further studies supported these findings, these values could be 
used to suggest if a patient is at lower risk of developing prolonged cytopenias.  
However, with this being the first study to identify this association, further research is 
needed before determining the predictiveness. 
 When examining clinical properties of the cytopenic cohort, we found that 82% of 
patients had been treated with RCHOP and RICE prior to CAR T-cell therapy. This is not 
surprising as RCHOP is the standard first line of therapy for patients with aggressive B-
cell NHL and RICE is a common salvage therapy option.8,13 However, we did find that 
receiving R-cytarabine as the most recent chemotherapy prior to CAR T-cell infusion was 
found to be associated with prolonged cytopenias through naïve Fisher exact test. 
Although the significance did not hold up to BH correction, it does indicate a need for 
further investigation to either confirm or deny any increased risk of prolonged cytopenias 
from receiving R-cytarabine.  
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 We further investigated all chemotherapy regimens patients had received prior to 
CAR T-cell infusion and found that both RICE and lenalidomide were associated with 
prolonged cytopenias through naïve Fisher exact testing. However, similarly to R-
cytarabine, these associations did not remain after BH correction. Therefore, they are not 
found to be significant, but does suggest further investigation into their association with 
prolonged cytopenias is warranted.  
Investigations into PFS and OS were found to show no significant difference 
between the cytopenic and non-cytopenic cohorts. Since our criteria for the cytopenic 
cohort was much more defined in terms of length of data, and some of the patients in both 
cohorts did not have up to 6 months of follow up data, it would be of interest to further 
investigate these relationships with longer follow up data.  
 In terms of AEs, all factors involved in CRS and ICANS and the rate of infections 
after CAR T-cell infusion were found not to have any significant associations to either 
cohort. Therefore, absence or presence of these AE are not predictive of prolonged 
cytopenias. Considering a prior study found that time to max grade CRS was associated 
with prolonged cytopenias, and our research did not find this association, more studies 
should be conducted to further investigate this as an associated factor. 38 
Considering the lack of research regarding prolonged cytopenias after CAR T-cell 
infusion, it is imperative that more studies are conducted to help better understand what 
factors either increase a patient’s risk or are predictive of a patient having prolonged 
cytopenias.  
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APPENDIX I: List of Variables Collected 
Below is a list of all the variables collected and analyzed within this study.  
 
• ID 
• Patient Name 
• Medical Record Number 
• Date of birth 
• Age at time of cell infusion 
• Alive 
• If deceased - date of death 
• Cause of death  
• Lymphoma histology (2016 WHO) 
• Date of Dx (of aggressive large 
cell lymphoma) 
• Stage at dx 
• Bone Marrow Involvement at dx 
• ECOG or KPS pre-CARs 
• IPI pre-lymphodepletion 
• # of lines of therapy pre-
leukapheresis 
• Prior Auto Transplant  
• Date of auto transplant 
 
• Date of relapse after auto 
• Prior Allogenic Transplant  
• Date of allogenic Transplant 
• Date of relapse after allogenic 
transplant 
• Name of most recent chemo 
regimen pre leukapheresis 
• Last date of chemotherapy prior to 
leukapheresis 
• Date of leukapheresis 
• ALC on date of leukapheresis 
• Date of day 1 of lymphodepletion 
• Baseline CRP pre lymphodepletion 
• Baseline Ferritin pre 
lymphodepletion 
• Baseline LDH pre lymphodepletion 
• G-CSF Pre-Infusion Y/N 
• G-CSF type 
• G-CSF date 
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• Date of cell infusion 
• Type of Product 
• Baseline CRP day 0 
• Baseline Ferritin day 0 
• Baseline LDH day 0 
• Baseline IgG day 0 
• Baseline CD4 day 0 
• Day of first fever (>100.4) 
• ANC on 1st day of fever (T>100.4) 
• ALC on date of 1st fever post CARs 
• Duration of fever (days) 
• Max temperature post CARS (C) 
• ALC on date of max temperature 
• CRP Max post CARs 
• Day of CRP Peak post CARs  
• Ferritin Max post CARS 
• Day of Ferritin peak post CARs ( 
• ALC Max post CARs 
• Day of ALC peak post CARs  
• Clinical CRS observed (Lee 
Criteria) 
• Duration of CRS (days) 
• Date of onset grade 2+ CRS  
• Max grade CRS 
• Day post CAR T infusion that max 
grade CRS was observed  
• ALC on date of observed max grade 
CRS 
• Was CRS self-limiting (ie - No 
cytokine directed therapy )  
• Tocilizumab given? 
• Number of doses of tocilizumab 
• >1 doses of tocilizumab 
• Date of first tocilizumab dose 
• CRS grade at time of tocilizumab 
dosing 
• Low dose steroids given for CRS  
• Number of doses of low dose 
steroids given 
• Evidence of ICANS 
• First day of ICANS 
• MAX grade ICANS 
• Duration of ICANS (days) 
• Low dose steroids given for ICANS  
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• # of doses of low dose steroids used 
for ICANS 
• Total number of steroids >4 (From 
CRS and ICANS) 
• Type of G-CSF during admission 
• Number of doses of G-CSF during 
admission 
• Date of initial admission to the 
hospital 
• Date of discharge from the hospital 
• Date of first restaging scan 
• Time after infusion of 1st scan 
(days) 
• Response on 1st restaging scan 
• Deauville score on restaging scan 
• Size of index target lesion post 
CARs 
• ALC on date of restaging scans 
• Scan #2-6 Date 
• Time after infusion of scan 2-6 
(days) 
• Response at Scan 2-6 
• Date of CR post CARs (If Achieved) 
• Relapse 
• Date of Relapse post CARs 
• Date of restaging bone marrow 
biopsy 
• ALC on date of restaging marrow  
• Type of G-CSF post-admission 
• Number of doses of G-CSF post-
admission (within 6 months of 
infusion) 
• IgG at timepoint 1-5 post-infusion 
• CD4 at timepoint 1-5 post-infusion 
• Timepoint 1-5 Date 
• Time after infusion of timepoint 1-5 
(Days) 
• Length of Stay 
• Hgb, PLT, and ANC Pre aph 
• Hgb, PLT and ANC Day 0 
• Hgb, PLT and ANC 1mo 
• Hgb, PLT and ANC 3mo 
• Hgb, PLT and ANC 6 mo 
• Date 1 mo 
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• Date 3mo 
• Date 6mo 
• IL-6 day 0 
• IL-6 Max 
• Day IL6- Max observed 




• GCSF Post Infusion 
• Infectious complications post 
infusion within 1 year 
• List Prior Lines of Systemic 
Therapy 
• Prior Radiation 
• Location of Radiation 
• Bone Marrow Biopsy post infusion 
o Date of bone marrow biopsy 
o MDS 
o AML 
o Comments on Cellularity 
o Dysplasia 





APPENDIX II: Evaluation and Grading Methods 
 
Table 13. ECOG Performance Status 
 
Grade ECOG Performance Status 
0 Fully active, able to carry on all pre-disease performance without 
restriction 
1 
Restricted in physical strenuous activity by ambulatory and able to carry 
out work of a light or sedentary nature, e.g., light house work, office 
work 
2 Ambulatory and capable of all selfcare but unable to carry out any work 
activities; up and about more than 50% of waking hours 
3 Capable of only limited selfcare; confined to bed or chair more than 50% 
of waking hours 
4 Completely disabled; cannot carry on any selfcare; totally confined to bed 
or chair 
5 Dead 
Criteria used to determine effects of disease and treatment toxicities on a patient’s daily 














Table 14. Risk Factors Involved in IPI 
 
IPI Risk Factors 
Age > 60 
Ann Arbor stage III or IV 
> 1 extranodal site 
Serum lactate dehydrogenase (LDH) level above normal 
ECOG performance status ³2 
Abbreviations: ECOG: Eastern Cooperative Oncology Group; IPI: International Prognostic Index 
Five risk factors used to predict patient’s level of risk from disease. The more risk factors equate to a 
higher risk patient. Adapted from M.A. Shipp et al., 1993.  
 
 
Table 15. The International Prognostic Index  
 
Risk Group IPI Score Percentage of Patients 5-year OS CR Rate 
Low 0-1 35% 73% 87% 
Low-
Intermediate 2 27% 51% 67% 
High- 
Intermediate 3 22% 43% 55% 
High 4-5 16% 26% 44% 
The IPI is used to predict treatment outcome and risk of reoccurrence of disease. Adapted 




Table 16. The Deauville Five Point Scale 
 
Score Definition 
1 No uptake 
2 Uptake £ mediastinum 
3 Uptake > mediastinum but £ liver 
4 Moderately increased uptake compared to the liver 
5 Markedly increased uptake compared to the liver and/or new lesions 
X New areas of uptake unlikely to be related to lymphoma 
The Deauville five point scale (D5PS) is used to standardize measuring of 
fluorodeoxyglucose (FDG) uptake in a patient. The FDG uptake is measured from the site 
with the most intense uptake and is compared to the values of FDG uptake of a patient’s 




Table 17. The Lugano Staging System 
 
Stage Involvement Extranodal (E) Status 
Limited   
I One node or a group of adjacent nodes Single extranodal lesions 
without nodal involvement 
II Two or more nodal groups on the same 
side of the diaphragm 
Stage I or II by nodal extent 
with limited contiguous 
extranodal involvement 
II bulky* II as above with “bulky” disease Not applicable 
Advanced   
III Nodes on both sides of the diaphragm; 
nodes above the diaphragm with spleen 
involvement 
Not applicable 
IV Additional noncontiguous 
extralymphatic involvement 
Not applicable 
The Lugano Staging System is used to help physicians standardize the extent of a 
patient’s disease and can help guide in determine appropriate treatment. Adapted from 
Chenson et al., 2014.  
*Whether stage II bulky disease is treated as limited or advanced disease may be 




Table 18. Tumor Response Classifications of the Lugano Criteria  
 
 
Abbreviations: D5PS: Deauville Five Point Scale; FDG: fluorodeoxyglucose 
The Lugano tumor response classifications identify a patient’s response to treatment. 




Table 19. Lee CRS Revised Grading System 
 
 
The Lee grading system is used to standardize the intensity of CRS and to help in 




Table 20. CTCAE ICANS Grading Criteria 
 
CTCAE Term Grade 1 Grade 2 Grade 3 Grade 4 












Definition: A disorder characterized by a pathologic process involving the brain. 
Seizure Brief partial 














Definition: A disorder characterized by a sudden, involuntary skeletal muscular contractions of cerebral 
or brain stem origin.  















Severe receptive or 
expressive 
characteristics; 






Definition: A disorder characterized by impairment of verbal communication skills, often resulting from 
brain damage.  






limiting self-care ADL 
N/A 
Definition: A disorder characterized by the uncontrolled shaking movement of the whole body or 
individual parts.  
Headache Mild pain Moderate pain; 
limiting 
instrumental ADL 




Definition: A disorder characterized by a sensation of marked discomfort in various parts of the head, 






































Definition: A disorder characterized by a decrease in ability to perceive and respond. 









Definition: A disorder characterized by swelling due to an excessive accumulation of fluid in the brain. 
ADL: Activities of daily living 
The CTCAE grading criteria for ICANS. Adapted from Common Terminology Criteria for Adverse 
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